A further issue is the potential risks of altering the VWF/ADAMTS13/endothelial cell axis, and the risk of triggering AVWS or TTP and their associated morbidity and mortality in these vulnerable patients. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.